|
Contents
|
|
|
|
Gliomas
|
|
|
|
Brock
CS,
Newlands ES, Wedge SR, Bower M, Evans H, Colquhoun I, Roddie M, Glaser M,
Brampton MH, Rustin GJ.
Phase I trial of temozolomide using an extended continuous oral schedule
Cancer Res 1998 Oct 1;58(19):4363-7
|
|
|
Metastatic
Tumors
|
|
|
|
Colleoni M, Rocca A, Sandri MT,
Zorzino L, Masci G, Nole F, Peruzzotti G, Robertson C, Orlando L, Cinieri S, de
BF, Viale G, Goldhirsch A
Low-dose
oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor
activity and correlation with vascular endothelial growth factor levels
Ann
Oncol 2002 Jan;13(1):73-80
|
|
|
Non-Nervous
System Tumors
|
|
|
|
Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly
MS, Folkman J
Antiangiogenic
scheduling of chemotherapy improves efficacy against experimental drug-resistant
cancer
Cancer Res 2000 Apr 1;60(7):1878-86 (PDF Full Text)
|
|
|
Man
S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ,
Bergers G, Kerbel RS
Antitumor
effects in mice of low-dose (metronomic) cyclophosphamide administered
continuously through the drinking water
Cancer
Res 2002 May 15;62(10):2731-5
|
|
